S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
pixel
NASDAQ:VIR

Vir Biotechnology - VIR Stock Forecast, Price & News

$30.17
+0.92 (+3.15%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.96
$30.21
50-Day Range
$22.09
$31.10
52-Week Range
$18.21
$58.00
Volume
771,601 shs
Average Volume
708,596 shs
Market Capitalization
$3.99 billion
P/E Ratio
3.33
Dividend Yield
N/A
Price Target
$61.33

Vir Biotechnology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
96.9% Upside
$59.40 Price Target
Short Interest
Healthy
9.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Vir Biotechnology in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $2.06 to ($3.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

195th out of 1,283 stocks

Biological Products, Except Diagnostic Industry

30th out of 197 stocks

VIR stock logo

About Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology Trading Up 3.1 %

Shares of VIR Stock traded up $0.92 on Friday, reaching $30.17. The company's stock had a trading volume of 771,601 shares, compared to its average volume of 708,596. The stock's fifty day simple moving average is $26.91 and its 200-day simple moving average is $26.12. Vir Biotechnology has a 1 year low of $18.21 and a 1 year high of $58.00. The company has a market capitalization of $3.99 billion, a price-to-earnings ratio of 3.33 and a beta of -0.40.

Vir Biotechnology (NASDAQ:VIR - Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $3.85 earnings per share for the quarter, beating analysts' consensus estimates of $3.21 by $0.64. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $811.05 million. Vir Biotechnology had a net margin of 52.29% and a return on equity of 96.39%. Vir Biotechnology's revenue for the quarter was up 59900.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.32) earnings per share. Equities research analysts forecast that Vir Biotechnology will post 2.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $125.00 price objective on shares of Vir Biotechnology in a research report on Thursday, July 14th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $59.40.

Insiders Place Their Bets

In other news, insider Phillip Pang sold 4,991 shares of Vir Biotechnology stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $24.89, for a total transaction of $124,225.99. Following the completion of the sale, the insider now directly owns 144,000 shares in the company, valued at $3,584,160. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Vicki L. Sato sold 14,541 shares of the business's stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $20.62, for a total transaction of $299,835.42. Following the sale, the director now owns 1,503,463 shares in the company, valued at $31,001,407.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Phillip Pang sold 4,991 shares of the business's stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $24.89, for a total value of $124,225.99. Following the sale, the insider now owns 144,000 shares in the company, valued at approximately $3,584,160. The disclosure for this sale can be found here. Insiders sold 67,049 shares of company stock valued at $1,747,779 over the last three months. 22.40% of the stock is owned by company insiders.

Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Stock News Headlines

3 Fast-Growing Stocks to Buy Now
Vir Biotechnology Inc Stock Quote VIR
2 Biotech Stocks That Could Help Make You a Fortune
BURGEONING BIOTECH HUB
See More Headlines
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Company Calendar

Last Earnings
11/04/2021
Today
8/07/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
444
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$59.40
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+103.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
5 Analysts

Profitability

Net Income
$528.58 million
Pretax Margin
70.53%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$4.08 per share
Book Value
$10.94 per share

Miscellaneous

Free Float
102,724,000
Market Cap
$3.99 billion
Optionable
Optionable
Beta
-0.40

Key Executives

  • Dr. George A. Scangos Ph.D. (Age 74)
    Pres, CEO & Director
    Comp: $1.07M
  • Mr. Howard Horn (Age 44)
    Exec. VP, CFO & Sec.
    Comp: $732.41k
  • Dr. Ann M. Hanly Ph.D. (Age 52)
    Exec. VP & Chief Technology Officer
    Comp: $922.22k
  • Dr. Herbert W. Virgin IV (Age 66)
    M.D., Ph.D., Exec. VP of Research & Chief Scientific Officer
    Comp: $1.12M
  • Dr. Phillip Pang M.D. (Age 47)
    Ph.D., Exec. VP & Chief Medical Officer
    Comp: $780.46k
  • Dr. Klaus Frueh Ph.D. (Age 62)
    Co-Founder & Scientific Advisor
  • Dr. Lawrence Corey
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Ms. Johanna Friedl-Naderer (Age 54)
    Exec. VP & COO
  • Mr. Steven J. Rice (Age 62)
    Exec. VP & Chief Admin. Officer













VIR Stock - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Vir Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIR, but not buy additional shares or sell existing shares.
View analyst ratings for Vir Biotechnology
or view top-rated stocks.

What is Vir Biotechnology's stock price forecast for 2022?

5 Wall Street analysts have issued 1-year target prices for Vir Biotechnology's stock. Their VIR stock forecasts range from $28.00 to $125.00. On average, they predict Vir Biotechnology's stock price to reach $59.40 in the next year. This suggests a possible upside of 96.9% from the stock's current price.
View analysts' price targets for Vir Biotechnology
or view top-rated stocks among Wall Street analysts.

How has Vir Biotechnology's stock price performed in 2022?

Vir Biotechnology's stock was trading at $41.87 at the beginning of 2022. Since then, VIR shares have decreased by 27.9% and is now trading at $30.17.
View the best growth stocks for 2022 here
.

When is Vir Biotechnology's next earnings date?

Vir Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our earnings forecast for Vir Biotechnology
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings data on Thursday, November, 4th. The company reported $0.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $1.12. The company had revenue of $103.62 million for the quarter, compared to analyst estimates of $138.25 million. Vir Biotechnology had a net margin of 52.29% and a trailing twelve-month return on equity of 96.39%. The firm's revenue for the quarter was up 5274.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.67) EPS.

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology CEO George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among Vir Biotechnology's employees.

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

What is Vir Biotechnology's stock symbol?

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.09%), Sector Gamma AS (0.08%), Bank Julius Baer & Co. Ltd Zurich (0.07%), State of New Jersey Common Pension Fund D (0.07%), New York State Teachers Retirement System (0.06%) and Yousif Capital Management LLC (0.05%). Company insiders that own Vir Biotechnology stock include Abu Dhabi Investment Authority, Ann M Hanly, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Vir Biotechnology
.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vir Biotechnology's stock price today?

One share of VIR stock can currently be purchased for approximately $30.17.

How much money does Vir Biotechnology make?

Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $3.99 billion and generates $1.10 billion in revenue each year. The company earns $528.58 million in net income (profit) each year or $9.05 on an earnings per share basis.

How many employees does Vir Biotechnology have?

Vir Biotechnology employs 444 workers across the globe.

How can I contact Vir Biotechnology?

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for Vir Biotechnology is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio.

This page (NASDAQ:VIR) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.